Arcadia Biosciences Inc (RKDA) - Net Assets
Based on the latest financial reports, Arcadia Biosciences Inc (RKDA) has net assets worth $4.14 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.55 Million) and total liabilities ($2.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Arcadia Biosciences Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.14 Million |
| % of Total Assets | 63.24% |
| Annual Growth Rate | N/A |
| 5-Year Change | -86.73% |
| 10-Year Change | -81.35% |
| Growth Volatility | 87.39 |
Arcadia Biosciences Inc - Net Assets Trend (2012–2025)
This chart illustrates how Arcadia Biosciences Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Arcadia Biosciences Inc market capitalisation.
Annual Net Assets for Arcadia Biosciences Inc (2012–2025)
The table below shows the annual net assets of Arcadia Biosciences Inc from 2012 to 2025. Also explore RKDA net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.14 Million | -33.47% |
| 2024-12-31 | $6.22 Million | -51.01% |
| 2023-12-31 | $12.70 Million | -39.22% |
| 2022-12-31 | $20.90 Million | -33.00% |
| 2021-12-31 | $31.20 Million | +9.26% |
| 2020-12-31 | $28.55 Million | +242.93% |
| 2019-12-31 | $8.33 Million | -35.03% |
| 2018-12-31 | $12.81 Million | +60.05% |
| 2017-12-31 | $8.01 Million | -63.93% |
| 2016-12-31 | $22.20 Million | -44.82% |
| 2015-12-31 | $40.23 Million | +2233.95% |
| 2014-12-31 | $-1.89 Million | +89.10% |
| 2013-12-31 | $-17.30 Million | -204.31% |
| 2012-12-31 | $-5.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcadia Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19878100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $65.00K | 1.57% |
| Other Components | $285.29 Million | 6891.11% |
| Total Equity | $4.14 Million | 100.00% |
Arcadia Biosciences Inc Competitors by Market Cap
The table below lists competitors of Arcadia Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Capital Gearing Trust
LSE:CGT
|
$982.73K |
|
Nuwellis Inc
NASDAQ:NUWE
|
$983.90K |
|
SEALAND CAP. GA. LS-0001
F:7KM
|
$984.05K |
|
GACM Technologies Limited
NSE:GATECHDVR
|
$984.56K |
|
Global Energy Metals Corp
V:GEMC
|
$977.61K |
|
Robert Walters
LSE:RWA
|
$976.42K |
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
$975.37K |
|
EJF Investments Ltd
LSE:EJFI
|
$968.26K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcadia Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,223,000 to 4,140,000, a change of -2,083,000 (-33.5%).
- Net loss of 2,339,000 reduced equity.
- Other factors increased equity by 256,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.34 Million | -56.5% |
| Other Changes | $256.00K | +6.18% |
| Total Change | $- | -33.47% |
Book Value vs Market Value Analysis
This analysis compares Arcadia Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.16x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-138.97 | $0.48 | x |
| 2013-12-31 | $-422.91 | $0.48 | x |
| 2014-12-31 | $-46.09 | $0.48 | x |
| 2015-12-31 | $1126.81 | $0.48 | x |
| 2016-12-31 | $400.27 | $0.48 | x |
| 2017-12-31 | $148.54 | $0.48 | x |
| 2018-12-31 | $136.10 | $0.48 | x |
| 2019-12-31 | $48.44 | $0.48 | x |
| 2020-12-31 | $111.36 | $0.48 | x |
| 2021-12-31 | $58.44 | $0.48 | x |
| 2022-12-31 | $35.09 | $0.48 | x |
| 2023-12-31 | $10.38 | $0.48 | x |
| 2024-12-31 | $4.56 | $0.48 | x |
| 2025-12-31 | $3.03 | $0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcadia Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -56.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48.15%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 1.58x
- Recent ROE (-56.50%) is above the historical average (-87.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -176.46% | 0.52x | 0.00x | $-11.80 Million |
| 2013 | 0.00% | -203.69% | 0.68x | 0.00x | $-11.47 Million |
| 2014 | 0.00% | -262.66% | 0.28x | 0.00x | $-18.15 Million |
| 2015 | -44.64% | -331.66% | 0.07x | 1.85x | $-21.98 Million |
| 2016 | -88.40% | -615.56% | 0.06x | 2.55x | $-21.84 Million |
| 2017 | -196.17% | -390.14% | 0.24x | 2.07x | $-16.51 Million |
| 2018 | -105.19% | -920.77% | 0.06x | 1.87x | $-14.76 Million |
| 2019 | -373.85% | -2464.07% | 0.04x | 4.23x | $-29.58 Million |
| 2020 | -16.79% | -57.94% | 0.17x | 1.71x | $-7.43 Million |
| 2021 | -47.15% | -216.22% | 0.15x | 1.41x | $-17.77 Million |
| 2022 | -73.10% | -207.28% | 0.26x | 1.38x | $-17.48 Million |
| 2023 | -108.88% | -313.90% | 0.23x | 1.53x | $-15.27 Million |
| 2024 | -113.10% | -139.50% | 0.37x | 2.17x | $-7.66 Million |
| 2025 | -56.50% | -48.15% | 0.74x | 1.58x | $-2.75 Million |
Industry Comparison
This section compares Arcadia Biosciences Inc's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $169,127,121
- Average return on equity (ROE) among peers: -13.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcadia Biosciences Inc (RKDA) | $4.14 Million | 0.00% | 0.58x | $982.16K |
| Above Food Ingredients Inc. Common Stock (ABVE) | $199.86 Million | -2.89% | 0.00x | $4.86 Million |
| Agape ATP Corporation Common Stock (ATPC) | $3.31 Million | -76.20% | 0.43x | $2.34 Million |
| B&G Foods Inc (BGS) | $835.46 Million | -7.92% | 3.15x | $244.45 Million |
| BioHarvest Sciences Inc. Common Stock (BHST) | $-59.57K | 0.00% | 0.00x | $36.27 Million |
| BranchOut Food Inc. Common Stock (BOF) | $-5.14 Million | 0.00% | 0.00x | $59.67 Million |
| Bellring Brands LLC (BRBR) | $-161.00 Million | 0.00% | 0.00x | $1.06 Billion |
| BRC Inc. (BRCC) | $95.94 Million | -86.42% | 1.35x | $216.27 Million |
| BRF SA ADR (BRFS) | $672.80 Million | 25.01% | 2.60x | $5.38 Billion |
| Bridgford Foods Corporation (BRID) | $50.80 Million | 17.13% | 0.49x | $53.01 Million |
| Borealis Foods Inc. (BRLS) | $-695.89K | 0.00% | 0.00x | $29.83 Million |
About Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief,… Read more